Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Mylan Introduces Critical Care Segment in India

By R&D Editors | March 12, 2014

Mylan Inc. announced that its subsidiary, Mylan Pharmaceuticals Private Ltd., has launched a Critical Care segment in India. The new segment focuses on anti-fungal, antibiotics and anti-coagulant therapies. AmBisome, a leading anti-fungal, is one of the first critical care products Mylan is offering. Critical care is a leading therapeutic category in India, with $2.6 billion in annual sales.
 
Mylan CEO Heather Bresch commented: “The introduction of Mylan’s Critical Care segment represents another milestone in the expansion of our commercial presence in India and supports our mission to expand access to high quality medicine around the world. Moreover, the Critical Care segment allows us to better satisfy the unmet medical needs of patients living with life-threatening diseases. The bacterial disease burden in India is among the highest in the world2 and as a result, critical care medicines play an increasingly important role in limiting morbidity and mortality.”
 
Bresch continued: “As an indicator of disease burden, pneumonia causes an estimated 410,000 deaths in India each year. Many of these deaths occur because patients do not have access to life-saving antibiotics. We look forward to playing a central role in expanding access to affordable, quality medicine that these individuals desperately need.”
 
Mylan President Rajiv Malik added, “This new segment further diversifies our product offerings in India. In the past 18 months alone, we have delivered on our commitment to providing high quality medicine to patients in India through the introduction of four unique and innovative segments– Antiretroviral, Women’s Care, Oncology and, now, Critical Care. We are pleased to offer AmBisome as one of our first critical care products, and we look forward to introducing several more high-growth critical care products, including high-end antibiotics, in the near future.”
 
AmBisome treats life-threatening, systemic fungal infections and the parasitic disease visceral leishmaniasis. The product is the innovator brand of Liposomal Amphotericin B and is widely accepted by hematologists, oncologists and intensivists for the treatment of suspected or definitive systemic fungal infections.
 
Date: March 11, 2014
Source: Mylan

Related Articles Read More >

2025 R&D layoffs tracker tops 92,000
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
DNA microscope offers new 3D view of organisms from the inside out
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE